Cargando…

A microcosting study of immunogenicity and tumour necrosis factor alpha inhibitor drug level tests for therapeutic drug monitoring in clinical practice

Objectives. To identify and quantify resource required and associated costs for implementing TNF-α inhibitor (TNFi) drug level and anti-drug antibody (ADAb) tests in UK rheumatology practice. Methods. A microcosting study, assuming the UK National Health Service perspective, identified the direct me...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jani, Meghna, Gavan, Sean, Chinoy, Hector, Dixon, William G., Harrison, Beverley, Moran, Andrew, Barton, Anne, Payne, Katherine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2016
Materias:	Clinical Science
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5144665/ https://www.ncbi.nlm.nih.gov/pubmed/27576368 http://dx.doi.org/10.1093/rheumatology/kew292

Ejemplares similares

Drug safety and immunogenicity of tumour necrosis factor inhibitors: the story so far
por: Jani, Meghna, et al.
Publicado: (2018)

Factors that influence rheumatologists’ anti-tumor necrosis factor alpha prescribing decisions: a qualitative study
por: Gavan, Sean P., et al.
Publicado: (2019)

The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases
por: Jani, Meghna, et al.
Publicado: (2014)

Therapeutic monitoring of TNF inhibitors for rheumatoid arthritis: evidence required following NICE’s recommendations
por: Gavan, Sean P, et al.
Publicado: (2020)

Detection of anti-drug antibodies using a bridging ELISA compared with radioimmunoassay in adalimumab-treated rheumatoid arthritis patients with random drug levels
por: Jani, Meghna, et al.
Publicado: (2016)

Drug-specific risk and characteristics of lupus and vasculitis-like events in patients with rheumatoid arthritis treated with TNFi: results from BSRBR-RA
por: Jani, Meghna, et al.
Publicado: (2017)

High frequency of antidrug antibodies and association of random drug levels with efficacy in certolizumab pegol-treated patients with rheumatoid arthritis: results from the BRAGGSS cohort
por: Jani, Meghna, et al.
Publicado: (2017)

Microcosting study of ICU costs in three European countries
por: Tan, SS, et al.
Publicado: (2008)

Direct costs of radiotherapy for rectal cancer: a microcosting study
por: Hanly, Paul, et al.
Publicado: (2015)

Estimating maternity ward birth attendant time use in India: a microcosting study
por: Lofgren, Katherine T, et al.
Publicado: (2022)

Microcosting Analysis of Diffuse Large B-Cell Lymphoma Treatment in Malawi
por: Painschab, Matthew S., et al.
Publicado: (2019)

Hospitalization Costs Due to Hypoglycemia in Patients with Diabetes: A Microcosting Approach
por: Ferreira, João P., et al.
Publicado: (2020)

EE335 A Multicenter Microcosting Study for COVID-19 in Brazil
por: Bertoglio Cardoso, R., et al.
Publicado: (2023)

Assessing Immunogenicity of Biologic Drugs in Inflammatory Joint Diseases: Progress Towards Personalized Medicine
por: Gehin, Johanna Elin, et al.
Publicado: (2022)

A microcosting study of microsurgery, LINAC radiosurgery, and gamma knife radiosurgery in meningioma patients
por: Tan, Siok Swan, et al.
Publicado: (2010)

A Checklist for the Conduct, Reporting, and Appraisal of Microcosting Studies in Health Care: Protocol Development
por: Ruger, Jennifer Prah, et al.
Publicado: (2016)

A microcosting analysis of ICU expenditure in the interval between brain death and organ donation
por: Bowtell, Meghan K., et al.
Publicado: (2023)

The adverse drug reactions to tumor necrosis factor alpha inhibitor
por: Park, Hye-Kyung, et al.
Publicado: (2014)

Financial Impact of Deep Sternal Wound Infections After Coronary Surgery: A Microcosting Analysis
por: Orlandi, Bianca Maria Maglia, et al.
Publicado: (2023)

Genomic Sequencing Procedure Microcosting Analysis and Health Economic Cost-Impact Analysis: A Report of the Association for Molecular Pathology
por: Sabatini, Linda M., et al.
Publicado: (2016)

Molecular design of hybrid tumour necrosis factor-alpha. II: The molecular size of polyethylene glycol-modified tumour necrosis factor-alpha affects its anti-tumour potency.
por: Tsutsumi, Y., et al.
Publicado: (1996)

Cost analysis of a mobile medical unit programme in Andhra Pradesh: a microcosting study protocol
por: Raikwar, Aakash Ashok, et al.
Publicado: (2021)

Development of a microcosting protocol to determine the economic cost of diagnostic genomic testing for rare diseases in Australia
por: Mordaunt, Dylan A, et al.
Publicado: (2023)

Metabolic effects of tumour necrosis factor alpha in NMRI mice.
por: Mahony, S. M., et al.
Publicado: (1990)

Generating evidence to inform health technology assessment of treatments for SLE: a systematic review of decision-analytic model-based economic evaluations
por: Gavan, Sean, et al.
Publicado: (2020)

Time trends and prescribing patterns of opioid drugs in UK primary care patients with non-cancer pain: A retrospective cohort study
por: Jani, Meghna, et al.
Publicado: (2020)

Expression of tumour necrosis factor alpha and its receptors in carcinoma of the breast.
por: Pusztai, L., et al.
Publicado: (1994)

Paradoxical Roles of Tumour Necrosis Factor-Alpha in Prostate Cancer Biology
por: Tse, Brian W. C., et al.
Publicado: (2012)

Colorectal cancer severity and survival in correlation with tumour necrosis factor-alpha
por: Stanilov, Noyko, et al.
Publicado: (2014)

Tumour Necrosis Factor Alpha in Intestinal Homeostasis and Gut Related Diseases
por: Ruder, Barbara, et al.
Publicado: (2019)

The anticancer drug mithramycin A sensitises tumour cells to apoptosis induced by tumour necrosis factor (TNF)
por: Duverger, V, et al.
Publicado: (2004)

Mixed method versus full top-down microcosting for organ recovery cost assessment in a French hospital group
por: Hrifach, Abdelbaste, et al.
Publicado: (2016)

Autocrine self-elimination of cultured ovarian cancer cells by tumour necrosis factor alpha (TNF-alpha).
por: Simonitsch, I., et al.
Publicado: (1998)

Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion
por: de Wilt, J H W, et al.
Publicado: (2000)

Thermal enhancement of both tumour necrosis factor alpha-induced systemic toxicity and tumour cure in rats.
por: van der Zee, J., et al.
Publicado: (1995)

Inhibition of tumour necrosis factor alpha production by activated T cells of rheumatoid arthritis patients by novel anti-folate drugs: an ex vivo pilot study
por: van der Heijden, JW, et al.
Publicado: (2005)

The economic case for precision medicine
por: Gavan, Sean P., et al.
Publicado: (2018)

Assessing the Joint Value of Genomic-Based Diagnostic Tests and Gene Therapies
por: Gavan, Sean P., et al.
Publicado: (2019)

The neutrophil migration induced by tumour necrosis factor alpha in mice is unaffected by glucocorticoids
por: Cecilio, C. A., et al.
Publicado: (1997)

Tumour necrosis factor-alpha polymorphism as one of the complex inherited factors in pemphigus.
por: Torzecka, Jolanta Dorota, et al.
Publicado: (2003)

Cannot write session to /tmp/vufind_sessions/sess_rlvvvatvnn7a0jn6kgjuepi1c2